Generic Provigil

 

 

Provigil is used to support wakefulness in adults with conditions involving excessive sleepiness, together with narcolepsy.

David Weinshenker, PhD, associate professor of human genetics at Emory University, Atlanta, has made some of the mouse studies Volkow cites.

Weinshenker gives consent to Volkow that Provigilshares at least one brain receptor with cocaine, but he downplays the drug's addiction potential.

For the most part people who use Provigilhave not reported euphoria or being high. It never causes stimulation like caffeine. In terms of addiction and withdrawal, it just doesn't do that.

Provigilhas been responsible for a wide number of disorders, including ADHD, autism, and depression. But it provides a major benefit over amphetamine-like stimulants in that it promotes wakefulness without the sleep rebound -- a need for extra sleep when the drug wears off.

Procigil chunks the brain receptors required by cocaine and methamphetamine. Researches are on going to discover whether this drug might help wine addicts from these life-threatening addictions.

But Volkow maintains that because drugs have very different effects in different people, Provigilmay very well be dangerously addictive to vulnerable individuals.

Anecdotal evidence of this drug addiction can be discovered on the non-judgmental Erowid web site, in a section where drug users report their experiences.

Some users have expressed they have got so addicted to this drug, they can’t think life without it.

Together with Xanax and Ambien, Provigilis classified by the Drug Enforcement Administration as a Schedule IV drug -- a controlled substance with low potential for abuse relative to Schedule III drugs such as codeine or anabolic steroids.

Provigilmaker Cephalon agrees with the NIDA position that this medicine should not be taken by healthy individuals. But the company says the product's label accurately describes the drug's abuse potential.

After several studies made by the DEA, the FDA, and other international regulatory agencies, it can be concluded that the potential risk of abuse and dependence is accurately reflected in the product labeling. It can be told that there is a low comparative potential for abuse with modafinil, which is at least in agreement with the DEA scheduling for Provigil.

The Volkow study appears in the March 18 issue of the Journal of the American Medical Association.